Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction

Journal of Urology

Volumn 175, Issue 3, 2006, Pages 999-1004

  Abrams, Paul ^a   Kaplan, Steven ^b   De Koning Gans, Hendrik J ^c   Millard, Richard ^d  

^a SOUTHMEAD HOSPITAL   (United Kingdom)

^b New York Presbyterian Hospital Columbia University Medical Center   (United States)

^c PFIZER INC   (United States)

^d PRINCE OF WALES HOSPITAL   (Australia)

Author keywords

Safety; Tolterodine; Urodynamics

Indexed keywords

PLACEBO; TOLTERODINE;

ADULT; AGED; ARTICLE; BACKACHE; BLADDER NECK STENOSIS; BRAIN INFARCTION; CELLULITIS; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTOMETRY; DEHYDRATION; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MICTURITION; OVERACTIVE BLADDER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEPSIS; SIDE EFFECT; THORAX PAIN; URINE RETENTION; XEROSTOMIA;

AGED; BENZHYDRYL COMPOUNDS; CRESOLS; DOUBLE-BLIND METHOD; HUMANS; MALE; MIDDLE AGED; MUSCARINIC ANTAGONISTS; PHENYLPROPANOLAMINE; URINARY BLADDER NECK OBSTRUCTION; URINARY INCONTINENCE;

EID: 32044449411     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(05)00483-0     Document Type: Article

References (20)

1. A.W. Thomas, P. Abrams Lower urinary tract symptoms, benign prostatic obstruction and the overactive bladder BJU Int 85 suppl 2000 57
2. I. Milsom, P. Abrams, L. Cardozo, R.G. Roberts, J. Thuroff, A.J. Wein How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study BJU Int 87 2001 760
3. W.F. Stewart, J.B. Van Rooyen, G.W. Cundiff, P. Abrams, A.R. Herzog, R. Corey Prevalence and burden of overactive bladder in the United States World J Urol 20 2003 327
4. M. Emberton, G.L. Andriole, J. de la Rosette, B. Djavan, K. Hoefner, R. Vela Navarrete Benign prostatic hyperplasia a progressive disease of aging men Urology 61 2003 267
5. C. de Nunzio, G. Franco, A. Rocchegiani, F. Iori, C. Leonardo, C. Laurenti The evolution of detrusor overactivity after watchful waiting, medical therapy and surgery in patients with bladder outlet obstruction J Urol 169 2003 535
6. A.W. Thomas, A. Cannon, E. Bartlett, J. Ellis-Jones, P. Abrams The natural history of lower urinary tract dysfunction in men the influence of detrusor underactivity on the outcome after transurethral resection of the prostate with a minimum 10-year urodynamic follow-up BJU Int 93 2004 745
7. J.E. Greenland, A.F. Brading The effect of bladder outflow obstruction on detrusor blood flow changes during the voiding cycle in conscious pigs J Urol 165 2001 245
8. T.J. Peters, J.L. Donovan, H.E. Kay, P. Abrams, J.J.M.C.H. de la Rosette, D. Porru The International Continence Society Benign Prostatic Hyperplasia study the bothersomeness of urinary symptoms J Urol 157 1997 885
9. J.V. Jolleys, J.L. Donovan, K. Nanchahal, T.J. Peters, P. Abrams Urinary symptoms in the community how bothersome are they? Br J Urol 74 1994 551
10. W.P.J. Witjes, J.J.M.C.H. de la Rosette, J.L. Donovan, T.J. Peters, P. Abrams, H.E. Kay The International Continence Society "Benign Prostatic Hyperplasia" study international differences in lower urinary tract symptoms and related bother J Urol 157 1997 1295
11. S.A. Kaplan, E.F. Ikeguchi, R.P. Santarosa, P.M. D'Alisera, J. Hendricks, A.E. Te Etiology of voiding dysfunction in men less than 50 years of age Urology 47 1996 836
12. M.J. Barry, F.J. Fowler Jr., M.P. O'Leary, R.C. Bruskewitz, H.L. Holtgrewe, W.K. Mebust The American Urological Association symptom index for benign prostatic hyperplasia J Urol 148 1992 1549
13. P. Abrams, S. Kaplan, R. Millard Tolterodine treatment is safe in men with bladder outlet obstruction (BOO) and symptomatic detrusor overactivity (DO) Neurourol Urodyn 20 2001 547
14. P. Abrams Bladder outlet obstruction index, bladder contractility index and bladder voiding efficiency three simple indices to define bladder voiding function BJU Int 84 1999 14
15. M. Chancellor, S. Freedman, D. Mitcheson, A. Antoci, G. Primus, A. Wein Tolterodine, an effective and well tolerated treatment for urge incontinence and other overactive bladder symptoms Clin Drug Invest 19 2000 83
16. P. Abrams, J. Malone-Lee, B. Jacquetin, J.J. Wyndaele, T. Tammela, U. Jonas Twelve-month treatment of overactive bladder efficacy and tolerability of tolterodine Drugs Aging 18 2001 551
17. R.A. Appell, P. Abrams, H.P. Drutz, P.E. Van Kerrebroeck, R. Millard, A. Wein Treatment of overactive bladder long-term tolerability and efficacy of tolterodine World J Urol 19 2001 141
18. P. Van Kerrebroeck, K. Kreder, U. Jonas, N. Zinner, A. Wein Tolterodine Study Group Tolterodine once-daily superior efficacy and tolerability in the treatment of the overactive bladder Urology 57 2001 414
19. A. Athanasopoulos, K. Gyftopoulos, K. Giannitsas, J. Fisfis, P. Perimenis, G. Barbalias Combination treatment with an α-blocker plus an anticholinergic for bladder outlet obstruction a prospective, randomized, controlled study J Urol 169 2003 2253
20. J.G. Malone-Lee, J.B. Walsh, M.F. Maugourd Tolterodine a safe and effective treatment for older patients with overactive bladder J Am Geriatr Soc 49 2001 700